arcellx.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $235.48MM
Arcellx develops novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/13/2021 | Series C | $120MM | $xx.xx | $377.76MM | Adage, Asymmetry, Caas Capital, Cambrian Bio, Cam Capital, Clough Capital, Lg Tech, New Enterprise Associates, Novo Holdings, Samsara Biocapital, Sixty Degree, Soleus Capital, Sr One, Surveyor Capital, Suvretta, Takeda Ventures, Terra Magnum Capital Partners | |
Price per Share
$xx.xx
Shares Outstanding
57,224,618
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Adage, Asymmetry, Caas Capital, Cambrian Bio, Cam Capital, Clough Capital, Lg Tech, New Enterprise Associates, Novo Holdings, Samsara Biocapital, Sixty Degree, Soleus Capital, Sr One, Surveyor Capital, Suvretta, Takeda Ventures, Terra Magnum Capital Partners
|
||||||
10/03/2019 | Series B-2 | $42.84MM | $xx.xx | $181.78MM | Aju Ib, Clough Capital, Jvc Investment Partners, Lg Tech, Mirae Asset Capital, Mirae Asset Venture Investment, New Enterprise Associates, Novo Holdings, Quan Capital, S.R. One, Takeda Ventures | |
Price per Share
$xx.xx
Shares Outstanding
21,958,284
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Aju Ib, Clough Capital, Jvc Investment Partners, Lg Tech, Mirae Asset Capital, Mirae Asset Venture Investment, New Enterprise Associates, Novo Holdings, Quan Capital, S.R. One, Takeda Ventures
|
||||||
10/03/2019 | Series B-1 | $42.84MM | $xx.xx | $181.78MM | Aju Ib, Clough Capital, Jvc Investment Partners, Lg Tech, Mirae Asset Capital, Mirae Asset Venture Investment, New Enterprise Associates, Novo Holdings, Quan Capital, S.R. One, Takeda Ventures | |
Price per Share
$xx.xx
Shares Outstanding
27,444,339
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Aju Ib, Clough Capital, Jvc Investment Partners, Lg Tech, Mirae Asset Capital, Mirae Asset Venture Investment, New Enterprise Associates, Novo Holdings, Quan Capital, S.R. One, Takeda Ventures
|
||||||
09/01/2017 | Series A | $29.8MM | $xx.xx | $37.24MM | Novo Ventures | |
Price per Share
$xx.xx
Shares Outstanding
29,795,227
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Novo Ventures
|